- Home
- AOD vs PHVS Comparison
AOD vs PHVS Comparison
Compare AOD & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AOD
- PHVS
- Stock Information
- Founded
- AOD 2006
- PHVS 2015
- Country
- AOD United Kingdom
- PHVS Switzerland
- Employees
- AOD N/A
- PHVS N/A
- Industry
- AOD Investment Managers
- PHVS Biotechnology: Pharmaceutical Preparations
- Sector
- AOD Finance
- PHVS Health Care
- Exchange
- AOD Nasdaq
- PHVS Nasdaq
- Market Cap
- AOD 862.4M
- PHVS 980.9M
- IPO Year
- AOD N/A
- PHVS 2021
- Fundamental
- Price
- AOD $9.04
- PHVS $23.00
- Analyst Decision
- AOD
- PHVS Buy
- Analyst Count
- AOD 0
- PHVS 6
- Target Price
- AOD N/A
- PHVS $37.17
- AVG Volume (30 Days)
- AOD 423.5K
- PHVS 71.6K
- Earning Date
- AOD 01-01-0001
- PHVS 08-13-2025
- Dividend Yield
- AOD 12.95%
- PHVS N/A
- EPS Growth
- AOD 213.63
- PHVS N/A
- EPS
- AOD 1.93
- PHVS N/A
- Revenue
- AOD $72,962,082.00
- PHVS N/A
- Revenue This Year
- AOD N/A
- PHVS N/A
- Revenue Next Year
- AOD N/A
- PHVS N/A
- P/E Ratio
- AOD $4.44
- PHVS N/A
- Revenue Growth
- AOD N/A
- PHVS N/A
- 52 Week Low
- AOD $6.99
- PHVS $11.51
- 52 Week High
- AOD $9.14
- PHVS $26.33
- Technical
- Relative Strength Index (RSI)
- AOD 66.00
- PHVS 70.21
- Support Level
- AOD $8.88
- PHVS $21.84
- Resistance Level
- AOD $9.00
- PHVS $24.41
- Average True Range (ATR)
- AOD 0.06
- PHVS 1.74
- MACD
- AOD -0.00
- PHVS 0.54
- Stochastic Oscillator
- AOD 100.00
- PHVS 76.27
About AOD abrdn Total Dynamic Dividend Fund of Beneficial Interest
Aberdeen Total Dynamic Dividend Fund is a diversified, closed-end management investment company. Its investment objective is to seek high current dividend income. The company also focuses on the long-term growth of capital as a secondary investment objective. The fund invests in foreign securities, including direct investments in securities of foreign issuers and investments in depositary receipts that represent indirect interests in securities of foreign issuers. Its portfolio consists of securities from Information Technology, Financial, Healthcare, and Industrials among other sectors.
About PHVS Pharvaris N.V.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.